Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg5/6 cls
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)Leerink PartnersPaul MatteisDowngradeMarket perform (from outperform)-14%$27.65
Matteis also lowered his target to $35 from $40. He remains "confident in the value proposition of pimavanserin" but believes the "Street numbers may overlook a collection of minor headwinds for the pimavanserin launch"

Read the full 519 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE